Exelixis (EXEL) Q2 2024 earnings summary

Executive summary

• Q2 2024 delivered record revenues of $637.2 million and net income growth, driven by the cabozantinib franchise, especially CABOMETYX in RCC, and a $150 million milestone from Ipsen.

• CABOMETYX maintained its leadership as the top TKI in RCC, with 41% TRx share and highest-ever market share in first-line RCC.

• Advanced regulatory and clinical milestones, including FDA acceptance of sNDA for cabozantinib in NET with a PDUFA date of April 3, 2025.

• Discontinued XB002 development to reallocate resources to higher-priority assets and pipeline programs.

• Completed $450 million stock repurchase and announced a new $500 million program through 2025.

Financial highlights

• Q2 2024 total revenues were $637.2 million, up 36% year-over-year, with net product revenues of $437.6 million.

• CABOMETYX net product revenues were $433.3 million, with 16% sequential and 7% year-over-year growth.

• Recognized a $150 million commercial milestone from Ipsen and $41 million in royalties from partners.

• GAAP net income was $226.1 million ($0.77 per diluted share); non-GAAP net income was $245.6 million ($0.84 per diluted share).

• Cash and investments totaled $1.4 billion as of June 30, 2024.

Outlook and guidance

• 2024 total revenue guidance is $1.975–$2.075 billion; net product revenues expected at $1.65–$1.75 billion.

• R&D expenses projected at $925–$975 million; SG&A at $450–$500 million; effective tax rate of 20–22%.

• Guidance excludes restructuring expenses announced in January 2024.

• Anticipate continued business development and clinical collaboration discussions, with a focus on late-stage GU/GI assets.